| Literature DB >> 17031399 |
T Powles1, A Young, A Sanitt, A Sammit, J Stebbing, D Short, M Bower, P M Savage, M J Seckl, P Schmid.
Abstract
It is thought that the time interval between the antecedent pregnancy and diagnosis of gestational trophoblastic tumours (GTTs) may influence the outcome of these patients. In this study, we investigate the significance of this time interval. Multivariate analysis was used to investigate if the time interval was of prognostic significance from our cohort of 241 high-risk patients with GTT. Subsequent cutpoint analysis was used to determine an optimal cutpoint for the interval covariate. The outcome of these patients was plotted according to the Kaplan-Meier method. The time interval was of prognostic significance on multivariate analysis. A period of greater than 2.8 years after pregnancy was found to be of most significance. The 5-year overall survival was 62.0% (95% CI: 47-76%) for greater than 2.8 years vs 94% (95% CI: 91-97%) for less than 2.8 years (P<0.001). Multivariate analysis showed the presence of liver metastasis and the number of metastasis was also of prognostic importance. The interval between antecedent pregnancy and diagnosis in high-risk GTT is of prognostic significance. This gives some insight into the pathogenesis of the disease.Entities:
Mesh:
Year: 2006 PMID: 17031399 PMCID: PMC2360575 DOI: 10.1038/sj.bjc.6603416
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Patient characteristics
|
|
|
| |
|---|---|---|---|
| Number | 241 | 200 | 41 |
| Median age | 30 (range 17–61) | 33 (range 17–54) | 35 (range 22–61) |
| Median Prognostic score (WHO). | 11 (range 8–32) | 11 (range 8–32) | 14 (range 9–32) |
| Median Prognostic score (FIGO). | 8 (range 4–20) | 8 (range 4–18) | 9 (range 5–20) |
| Median follow-up | 11.7 years | 11.9 years | 6.2 years |
| Range 0.1–23.8 | Range 0.9–23.8 | Range 0.1–23.8 | |
| Median HCG at presentation | 190 000 | 200 000 | 72 000 |
| 300–3.4 million | 300–3.3million | 450–3.4million | |
|
| |||
| EMA/CO | 206 (85%) | 174 (87%) | 32 (80%) |
| EP/EMA | 14 (6%) | 9 (5%) | 5 (12%) |
| EMA/CNS | 17 (7%) | 14 (7%) | 3 (7%) |
| Other | 4 (1%) | 3 (2%) | 1 (1%) |
|
| |||
| Term | 125 (52%) | 96 (48%) | 29 (70%) |
| Abortion/unknown | 37 (15%) | 32 (16%) | 6 (15%) |
| Molar | 79 (33%) | 73 (35%) | 6 (15%) |
|
| |||
| Pulmonary | 98 (41%) | 77 (39%) | 21 (51%) |
| Extrapulmonary | 38 (16%) | 30 (15%) | 8 (20%) |
| Both | 26 (10%) | 18 (9%) | 8 (20%) |
| Deaths | 27 (11%) | 12 (6%) | 15 (37%) |
| Cancer-related deaths | 23 (10%) | 10 (5%) | 13 (32%) |
| 5-year survival | 87.4% | 94.0% | 62.0% |
| 95% CI: (77.8–96.8) | 95% CI: (91.3–97.0%) | (95% CI: 47.2–76.8%) | |
CI=confidence interval; CNS=central nervous system; EMA=epithelial membrane antigen; FIGO=International Federation of Gynecologic and Obstetrics; WHO=World Health Organization.
Figure 1(A) Cutpoint analysis investigating the most significant time point between pregnancy and diagnosis. (A) Interval vs coefficient for that interval, used to derive the interval cutoff limit. Dotted lines show 95% confidence intervals. Lower rug plot shows number of measurements at each interval. (B) Comparison of patients with a time period of less and more than 2.8 years since the antecedent pregnancy. Log rank P<0.0001. Actuarial 5-year OS: 0–2.8 years=94.0% (91–97%) >2.8 years=62.0% (47–76%).